Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Harnessing Function of Emt in Cancer Drug Resistance: A Metastasis Regulator Determines Chemotherapy Response Publisher Pubmed



Ebrahimi N1 ; Manavi MS2 ; Faghihkhorasani F3 ; Fakhr SS4 ; Baei FJ5 ; Khorasani FF6 ; Zare MM6 ; Far NP7 ; Rezaeitazangi F8 ; Ren J9 ; Reiter RJ10 ; Nabavi N11 ; Aref AR12, 13 ; Chen C14 Show All Authors
Authors
  1. Ebrahimi N1
  2. Manavi MS2
  3. Faghihkhorasani F3
  4. Fakhr SS4
  5. Baei FJ5
  6. Khorasani FF6
  7. Zare MM6
  8. Far NP7
  9. Rezaeitazangi F8
  10. Ren J9
  11. Reiter RJ10
  12. Nabavi N11
  13. Aref AR12, 13
  14. Chen C14
  15. Ertas YN15, 16
  16. Lu Q14
Show Affiliations
Authors Affiliations
  1. 1. Genetics Division, Department of Cell and Molecular Biology and Microbiology, Faculty of Science and Technology, University of Isfahan, Isfahan, Iran
  2. 2. Otolaryngology Department, Tehran University of Medical Science, Tehran, Iran
  3. 3. Medical Campus, Xi’an Jiaotong University, Shaanxi Province, Xi’an, China
  4. 4. Department of Biotechnology, Faculty of Applied Ecology, Agricultural Science and Biotechnology, Campus Hamar, Inland Norway University of Applied Sciences, Hamar, Norway
  5. 5. Amol University of Special Modern Technologies, Amol, Iran
  6. 6. Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
  7. 7. Department of Microbiology, Faculty of Advanced Science and Technology, Tehran Medical Science, Islamic Azad University, Tehran, Iran
  8. 8. Department of Anatomy, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran
  9. 9. Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, 200032, China
  10. 10. Department of Cellular and Structural Biology, UT Health Science Center, San Antonio, 77030, TX, United States
  11. 11. Department of Urologic Sciences and Vancouver Prostate Centre, University of British Columbia, Vancouver, V6H3Z6, BC, Canada
  12. 12. Translational Medicine Group, Xsphera Biosciences, 6 Tide Street, Boston, 02210, MA, United States
  13. 13. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States
  14. 14. Department of Cardiology, Affiliated Hospital of Nantong University, Jiangsu, 226001, China
  15. 15. ERNAM-Nanotechnology Research and Application Center, Erciyes University, Kayseri, 38039, Turkey
  16. 16. Department of Biomedical Engineering, Erciyes University, Kayseri, 38039, Turkey

Source: Cancer and Metastasis Reviews Published:2024


Abstract

Epithelial-mesenchymal transition (EMT) is a complicated molecular process that governs cellular shape and function changes throughout tissue development and embryogenesis. In addition, EMT contributes to the development and spread of tumors. Expanding and degrading the surrounding microenvironment, cells undergoing EMT move away from the main location. On the basis of the expression of fibroblast-specific protein-1 (FSP1), fibroblast growth factor (FGF), collagen, and smooth muscle actin (-SMA), the mesenchymal phenotype exhibited in fibroblasts is crucial for promoting EMT. While EMT is not entirely reliant on its regulators like ZEB1/2, Twist, and Snail proteins, investigation of upstream signaling (like EGF, TGF-β, Wnt) is required to get a more thorough understanding of tumor EMT. Throughout numerous cancers, connections between tumor epithelial and fibroblast cells that influence tumor growth have been found. The significance of cellular crosstalk stems from the fact that these events affect therapeutic response and disease prognosis. This study examines how classical EMT signals emanating from various cancer cells interfere to tumor metastasis, treatment resistance, and tumor recurrence. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.
Related Docs
View other Related Docs
1. The Critical Role of Circular Rnas in Drug Resistance in Gastrointestinal Cancers, Medical Oncology (2023)
2. Resveratrol in Breast Cancer Treatment: From Cellular Effects to Molecular Mechanisms of Action, Cellular and Molecular Life Sciences (2022)
3. The Impact of Epithelial-Mesenchymal Transition (Emt) Induced by Metabolic Processes and Intracellular Signaling Pathways on Chemo-Resistance, Metastasis, and Recurrence in Solid Tumors, Cell Communication and Signaling (2024)
4. Mirna-Mediated Khsrp Silencing Rewires Distinct Post-Transcriptional Programs During Tgf-Β-Induced Epithelial-To-Mesenchymal Transition, Cell Reports (2016)
5. Cross-Talk Between Non-Ionizing Electromagnetic Fields and Metastasis; Emt and Hybrid E/M May Explain the Anticancer Role of Emfs, Progress in Biophysics and Molecular Biology (2023)
6. The Molecular Signature of Breast Cancer Metastasis to Bone, Anti-Cancer Drugs (2016)
7. Lung Cancer-Associated Brain Metastasis: Molecular Mechanisms and Therapeutic Options, Cellular Oncology (2017)
8. A Truncated Snail1 Transcription Factor Alters the Expression of Essential Emt Markers and Suppresses Tumor Cell Migration in a Human Lung Cancer Cell Line, Recent Patents on Anti-Cancer Drug Discovery (2019)
Experts (# of related papers)
View all Related Experts
Gholamali Kardar (3)
Reza Shirkoohi (2)
Other Related Docs
9. The Microrna Let-7 and Its Exosomal Form: Epigenetic Regulators of Gynecological Cancers, Cell Biology and Toxicology (2024)
10. The Importance of the Circrna/Wnt Axis in Gliomas: Biological Functions and Clinical Opportunities, Pathology Research and Practice (2024)
11. The Evaluation of the N-Cadherin Promoter’S Ability to Block Emt by Specific Expression of Diphtheria Toxin in Emt-Induced A549 Cell Lines, Iranian Journal of Allergy# Asthma and Immunology (2024)
12. Tumor-Associated Macrophages and Epithelial–Mesenchymal Transition in Cancer: Nanotechnology Comes Into View, Journal of Cellular Physiology (2018)
13. Unraveling the Function of Epithelial-Mesenchymal Transition (Emt) in Colorectal Cancer: Metastasis, Therapy Response, and Revisiting Molecular Pathways, Biomedicine and Pharmacotherapy (2023)
14. Epithelial-To-Mesenchymal Transition in Thyroid Cancer: A Comprehensive Review, Endocrine (2019)
15. Glance Into Cancer Stem Cells, Journal of Kerman University of Medical Sciences (2016)
16. Competitive Effect of Overexpressed C-Terminal of Snail-1 (Csnail) in Control of the Growth and Metastasis of Melanoma Cells, Recent Patents on Anti-Cancer Drug Discovery (2024)
17. Role of the Wnt and Gtpase Pathways in Breast Cancer Tumorigenesis and Treatment, Cytokine and Growth Factor Reviews (2022)
18. Maml1 and Twist1 Co-Overexpression Promote Invasion of Head and Neck Squamous Cell Carcinoma, Asia-Pacific Journal of Clinical Oncology (2018)
19. Therapeutic Targeting of Tgf-Β in Lung Cancer, FEBS Journal (2025)
20. Targeting Cancer-Associated Fibroblasts With Pirfenidone: A Novel Approach for Cancer Therapy, Tissue and Cell (2024)
21. Unlocking the Secrets of Cancer Stem Cells With -Secretase Inhibitors: A Novel Anticancer Strategy, Molecules (2021)
22. Overexpression and Translocation of Dynamin 2 Promotes Tumor Aggressiveness in Breast Carcinomas, EXCLI Journal (2020)
23. Functions of the Snai Family in Chondrocyte-To-Osteocyte Development, Annals of the New York Academy of Sciences (2021)
24. Pro-Tumorigenic Functions of Macrophages at the Primary, Invasive and Metastatic Tumor Site, Cancer Immunology# Immunotherapy (2020)
25. Differential Bmi1, Twist1, Snai2 Mrna Expression Pattern Correlation With Malignancy Type in a Spectrum of Common Cutaneous Malignancies: Basal Cell Carcinoma, Squamous Cell Carcinoma, and Melanoma, Clinical and Translational Oncology (2017)
26. Immune Checkpoints and Ncrnas: Pioneering Immunotherapy Approaches for Hematological Malignancies, Cancer Cell International (2024)
27. Tlr4 Blockade Using Tak-242 Suppresses Ovarian and Breast Cancer Cells Invasion Through the Inhibition of Extracellular Matrix Degradation and Epithelial-Mesenchymal Transition, European Journal of Pharmacology (2019)
28. Metastatic Breast Cancer at a Glance: Scenarios of Bc Brain- and Bc Bone-Metastasis by Illustrations, Cancer Genetics and Psychotherapy (2017)
29. Two Novel Tri-Aryl Derivatives Attenuate the Invasion-Promoting Effects of Stromal Mesenchymal Stem Cells on Breast Cancer, Anti-Cancer Agents in Medicinal Chemistry (2019)
30. Competing Endogenous Rnas Regulatory Crosstalk Networks: The Messages From the Rna World to Signaling Pathways Directing Cancer Stem Cell Development, Heliyon (2024)
31. Enrichment of Cancer Stem-Like Cells by the Induction of Epithelial-Mesenchymal Transition Using Lentiviral Vector Carrying E-Cadherin Shrna in Ht29 Cell Line, Journal of Cellular Physiology (2019)
32. Upregulation of Circulating Cancer Stem Cell Marker, Dclk1 But Not Lgr5, in Chemoradiotherapy-Treated Colorectal Cancer Patients, Tumor Biology (2015)
33. Role of Non-Coding Rnas As New Therapeutic Targets in Regulating the Emt and Apoptosis in Metastatic Gastric and Colorectal Cancers, Cell Cycle (2023)
34. Association Between Micrornas and Chemoresistance in Pancreatic Cancer: Current Knowledge, New Insights, and Forthcoming Perspectives, Pathology Research and Practice (2022)
35. Gastric Cancer Stem Cells Effect on Th17/Treg Balance; a Bench to Beside Perspective, Frontiers in Oncology (2019)
36. Investigation of Specific Binding of Designed Oligodeoxynucleotide Decoys to Transcription Factors in Ht29 Cell Line Undergoing Epithelial–Mesenchymal Transition (Emt), Journal of Cellular Physiology (2019)
37. Circular Rnas (Circrnas) in Cancer Proliferation: Molecular Interactions and Possible Therapeutic Targets, Non-coding RNA Transcripts In Cancer Therapy: Pre-clinical And Clinical Implications (2023)
38. Cytoplasmic Expression of Twist1, an Emt-Related Transcription Factor, Is Associated With Higher Grades Renal Cell Carcinomas and Worse Progression-Free Survival in Clear Cell Renal Cell Carcinoma, Clinical and Experimental Medicine (2018)
39. Melatonin Targeting Non-Coding Rnas in Cancer: Focus on Mechanisms and Potential Therapeutic Targets, European Journal of Pharmacology (2023)
40. Lung Cancer and Mirnas: A Possible Remedy for Anti-Metastatic, Therapeutic and Diagnostic Applications, Expert Review of Respiratory Medicine (2017)
41. Melatonin for Gastric Cancer Treatment: Where Do We Stand?, Naunyn-Schmiedeberg's Archives of Pharmacology (2025)
42. Non-Coding Rnas in Leukemia Drug Resistance: New Perspectives on Molecular Mechanisms and Signaling Pathways, Annals of Hematology (2024)
43. Stat3 Signaling in Prostate Cancer Progression and Therapy Resistance: An Oncogenic Pathway With Diverse Functions, Biomedicine and Pharmacotherapy (2023)
44. Wnt5a and Tgfβ1 Converges Through Yap1 Activity and Integrin Alpha V Up-Regulation Promoting Epithelial to Mesenchymal Transition in Ovarian Cancer Cells and Mesothelial Cell Activation, Cells (2022)
45. Biological Landscape and Nanostructural View in Development and Reversal of Oxaliplatin Resistance in Colorectal Cancer, Translational Oncology (2024)
46. Role of Non-Coding Rnas in the Response of Glioblastoma to Temozolomide, Molecular Neurobiology (2025)
47. Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms, Vaccines (2022)
48. Recent Advances in Gene Therapy: Genetic Bullets to the Root of the Problem, Clinical and Experimental Medicine (2023)
49. Expression of Villin Associated With Epithelial to Mesenchymal Transition in Patients With Gastric Cancer Relating to Their Clinical and Morphological Specifications, Asia Pacific Journal of Cancer Biology (2020)
50. Non-Coding Rnas and Glioblastoma: Insight Into Their Roles in Metastasis, Molecular Therapy Oncolytics (2022)